Gene · 2050
Papers2,238
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,238
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clinical and molecular characterization of non-PIK3CA-related vascular malformations with overgrowth in a pediatric cohort. | World J Pediatr | 2026 | 42814223 | PubTator, text mining | PubMed |
| Discovery of Sennoside A as a Natural O-GlcNAcase Inhibitor That Ameliorates Parkinson's Disease by Restoring EphrinB2 O-GlcNAcylation. | Research (Wash D C) | 2026 | 42718897 | PubTator, text mining | PubMed |
| Macrophages Drive Ferroptosis Resistance after Radiotherapy. | Cancer Commun (Lond) | 2026 | 42698964 | PubTator, text mining | PubMed |
| Proteome-wide genetic study identified therapeutic targets for early-onset and late-onset Alzheimer's disease. | Int J Surg | 2026 | 42682321 | PubTator, text mining | PubMed |
Retraction notice to "Biological function of EPHB4 in the aging process of vascular endothelial cells: mtDNA molecular mechanism and MAPK/PGC-1/TFAM signaling pathway" [Int. J. Biol. Macromol. 293 (2025) 138536]. | Int J Biol Macromol | 2026 | 42527189 | PubTator, text mining | PubMed |
| Identification and analysis of EphrinB2/EphB4 signaling pathway and angiogenesis related biomarkers in coronary artery disease based on bioinformatics. | J Cardiothorac Surg | 2026 | 42477815 | PubTator, text mining | PubMed |
| Periodontitis as a Model for Inflammatory Uncoupling of Bone Remodeling. | J Periodontal Res | 2026 | 42403364 | PubTator, text mining | PubMed |
| EphB4 inhibition defines a druggable synthetic-lethal vulnerability in MYC-driven triple-negative breast cancer. | Cell Death Dis | 2026 | 42362505 | PubTator, text mining | PubMed |
| Capillary Malformation-Arteriovenous Malformation Syndrome Associated with RASA1 and EPHB4 Mutations: Comparative Case Series and Narrative Review. | Life (Basel) | 2026 | 42355527 | PubTator, text mining | PubMed |
| Homoharringtonine Impedes Migration and Invasion by Inhibiting EphB4/SRI/EMT Signaling and Enhances the Antimetastatic Abilities of Erlotinib in Pancreatic Cancer. | Curr Cancer Drug Targets | 2026 | 42333561 | PubTator, text mining | PubMed |
| The Frontiers of Orthodontically Induced Inflammatory Root Resorption: Mechanism, Treatment, and Future Prospects. | J Endod | 2026 | 42331141 | PubTator, text mining | PubMed |
| EphB4/EphrinB2 signaling regulates pericyte-like function of DPSCs in angiogenesis via transcriptional factor SRF. | Stem Cell Res Ther | 2026 | 42298719 | PubTator, text mining | PubMed |
| mRNA-LNP vaccine providing antigen and co-stimulation in the tumor microenvironment enhances CAR T cell function (CART-Vac). | Mol Ther Oncol | 2026 | 42256207 | PubTator, text mining | PubMed |
| Dual-ligand-modified cantharidin nanoparticles for the treatment of hepatocellular carcinoma via the inhibition of Ephb4. | Drug Deliv | 2026 | 42249613 | PubTator, text mining | PubMed |
| Fusion Gene EPHB4-MET Driven by HOXA9 and Exerted Oncogenic Activity in Non-Small Cell Lung Cancer. | Crit Rev Immunol | 2026 | 42224677 | PubTator, text mining | PubMed |
| A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations. | Clin Cancer Res | 2026 | 42126547 | PubTator, text mining | PubMed |
| Assessment of angiopoietin-1, angiopoietin-2, Tie-2, EphrinB2, EphB4, and endocan serum level in patients with Behçet disease: A cross-sectional observational study. | Medicine (Baltimore) | 2026 | 42071810 | PubTator, text mining | PubMed |
| Alveolar Bone Regeneration: Smart Biomaterials and Physical Stimulation. | J Biomed Mater Res B Appl Biomater | 2026 | 42032797 | PubTator, text mining | PubMed |
| Scalable Engineering of Bio-Manufactured Extracellular Vesicles for Selective Delivery in Ovarian Cancer Patient-Derived Models. | Adv Sci (Weinh) | 2026 | 42023984 | PubTator, text mining | PubMed |
| Detection rate and mutational landscape in extracranial arteriovenous malformations: a cohort study. | BMC Med | 2026 | 41987212 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2050/papers